Gentiva® Cardiopulmonary is a home-based disease management program that demonstrated increased patient functionality, reduced hospitalizations and emergency room visits, and improved compliance in the taking of medications; according to a two-year national study of more than 700 Gentiva® Cardiopulmonary patients:

• 92% of patients were able to perform activities of daily living at the time they were discharged from the program and 16 weeks after discharge.
Only 38% said they could perform such activities when they were admitted
to Gentiva Cardiopulmonary.

• 96% of patients required no further hospitalization 16 weeks after
discharge.

• Only 10% of patients required an emergency room visit after discharge
from the program, and this figure dropped to 6% within 16 weeks after
discharge. Approximately 71% required such visits when they were admitted to the program.

•91% of patients said they could explain the actions of their medications
upon discharge and this figure increased to 99% 16 weeks after discharge.
About 51% said they had this capability when they were admitted.

• 91% said they understood the side effects of their medications upon
discharge and the number rose to 96% 16 weeks after discharge. Upon
admission, only 43% said they had such an understanding.

Gentiva® Cardiopulmonary is designed to prevent the progression of heart- and lung-related diseases, assist patients and their physicians in managing those diseases, and control expenditures for health insurers by limiting or eliminating the need for more costly institutional care.

Read the full report.

Photo Credit: Gentiva